enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 100 shares, a drop of 50.0% from the February 28th total of 200 shares. Based on an average daily volume of 9,700 shares, the short-interest ratio is presently 0.0 days.

enGene Stock Down 8.8 %

Shares of ENGNW stock traded down $0.06 during trading on Friday, hitting $0.62. 4,254 shares of the stock traded hands, compared to its average volume of 12,850. enGene has a 52-week low of $0.42 and a 52-week high of $5.35. The firm’s fifty day moving average price is $0.82 and its 200-day moving average price is $1.23.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.